Mesoblast Limited (MESO) has received FDA clearance to initiate a registrational clinical trial for Ryoncil (Remestemcel-L-rknd) in treating Duchenne muscular dystrophy (DMD), a genetic disorder affecting approximately 15,000 children in the U.S. This marks a significant step for Mesoblast, as Ryoncil is the first mesenchymal stromal cell product approved by the FDA and is currently used for steroid-refractory acute graft-versus-host disease in pediatric patients.

The trial will involve 76 children aged 5 to 9 years, assessing the efficacy of Ryoncil in preserving muscle function and slowing disease progression. The primary endpoint is time-to-stand at nine months, a validated measure for FDA approval. This development could enhance Mesoblast’s market position, especially as Ryoncil approaches $100 million in revenue within its first year of launch.

For investors, the key takeaway is that successful trial outcomes could unlock new revenue streams for Mesoblast, potentially driving stock performance and increasing market interest in the biotech sector focused on rare diseases.

Source: nasdaq.com